Longevity sector focus at Davos

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Longevity remains key focus at World Economic Forum 2023.

Longevity has stayed in the limelight on the streets of Davos for the second time during this year’s World Economic Forum (WEF), and as well it should, given that the world’s population is growing – and aging – at a rapid rate.

Longevity.Technology: It is estimated that nearly a third of the world’s population will be over 60 years old by 2050, which begs the question: “How do we prepare to age healthily and live a long, happy life?”.

Enter the Longevity Investors Lunch, a satellite event focusing on longevity and rejuvenation during the World Economic Forum. The lunch took place on 18th January and discussed the latest technologies and research among prominent scientists, academia, entrepreneurs and investors. Co-organised by Maximon, Longevity Investors Conference and Biolytica, the lunch serves as a prelude to the Longevity Investors Conference, which is happening later this year, on 27-29 September, at Le Grand Bellevue Hotel in Gstaad, Switzerland.

Demonstrating how far the longevity industry has come, over 50 high level investors and key opinion leaders gathered together to focus of the event was on change and transformation of global health, innovative technologies and many more.

The two panels, moderated by Sabinije von Gaffke (Head of Sustainability, Nibiru Software) covered Longevity as the mega trend where the latest discoveries in research were discussed, as well as shedding light on the longevity investment landscape. The discussions on stage featured renowned experts and prominent longevity venture builders such as Professor Dr Björn Schumacher (Professor and Director, Institute for Genome Stability in Ageing and Disease, University of Cologne), Dr Brian Kennedy (Director, Centre for Healthy Longevity and Professor Departments of Biochemistry and Physiology at National University of Singapore), Dr Dina Radenkovic (Co-founder & CEO of Gameto & Partner, SALT), Dr Collin Ewald (Assistant Professor, ETH Zurich and Founder of Swiss Society for Aging Research), Jörg Rieker (Founding Partner, Maximon), Dr Kemal Tunc Tiryaki (Founder, MAGE Group) and Christian Schmid (Head Asset Management, Kaleido Privatbank).

Biolytica’s CEO Dr Rob Konrad Maciejewski gave a talk on Using the power of data to change healthcare and optimize longevity, in which gave the audience valuable insight into Biolytica’s new health data platform. Biolytica NEXUS is a tool for healthcare professionals such as longevity clinics, centres for preventive medicine, longevity physicians and others that uses AI and advanced analytics to combine genomics, epigenetics, biomarkers, wearable device data, lifestyle information such as nutrition and many others to create hyper-personalised health and longevity journeys for patients.

The hosts of the event, Dr Tobias Reichmuth (Co-Founder, Maximon & Longevity Investors Conference), Marc P Bernegger (Co-Founder, Maximon & Longevity Investors Conference) and Dr Rob Konrad Maciejewski (Co-Founder & CEO, Biolytica) opened the event with an overview of the longevity industry and closed it by explaining why company building in longevity is needed now.

“We are very proud to be one of the first ones to bring the important topic of longevity to Davos,” says Marc P Bernegger, Founding Partner at Maximon and the organiser of the Longevity Investors Conference in Gstaad. “We are already looking forward to the Longevity Investors Conference, where we will have the opportunity to continue the important conversations we started in Davos and involve more longevity leaders on stage who will talk about important developments in the longevity industry as well as investment opportunities in the field.”

Dr Rob Konrad Maciejewski adds: “A common misconception about longevity is that it’s only about adding more years to the clock of life. And a lot of people rightfully ask: ‘Why would I even want to spend more miserable years at old age?` But the concept of longevity is different and goes far beyond that.

“The current healthcare systems around the globe are, in essence, sick-care systems – we wait for people to become ill, and then spend billions of dollars to manage chronic diseases with medications – at greatly reduced quality of life. This is not sustainable, and not ethical. Longevity is not about just “adding years” – it’s mainly about developing strategies to keep people healthier for as long as possible, to extend the time we can spend in great health, to greatly improve their quality of life as they age – and if we can then add a few more healthy years, that’s a bonus. We believe the key to this is to better understand the human body, and the key to that is data, which is what Biolytica is focusing on.”

The Longevity Investors Conference is the most exclusive conference for longevity investors. It provides relevant insights into the longevity subject, expert education, investment opportunities and excellent networking opportunities in an exclusive location.

The motivation to organise the Longevity Investors Conference, said Dr. Tobias Reichmuth, Founding Partner and organiser, is clear: “The longevity industry is highly attractive for investors. We state a lack of education and information for investors and want to change this. While there are scientific-oriented conferences, a professional and global investor focused longevity conference was missing so far.”

Longevity now ranks as one of the most significant forces shaping the global economy, opening up multi-trillion dollar opportunities to reshape societies, hopefully for the better. It has experienced an unprecedented advance over recent years, particularly with the discovery that the rate of aging is controlled, at least to some extent, by genetic pathways and biochemical processes. It will be one of the largest, if not the largest investment opportunity in the decades to come.

Check out more of our coverage on Longevity Investors Conference HERE or register your interest for the 2023 conference HERE.

Interested in longevity investment? Visit our investment portal HERE

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE